This research explores the sex-based differences in the development and treatment of medulloblastoma (MB), specifically focusing on the Sonic Hedgehog (SHH) molecular subtype. The study identifies Yes-associated protein 1 (Yap1) as a critical oncogene that functions differently in males and females, showing that its removal significantly increases survival rates in males. This improvement is driven by a heightened immune response, where the loss of Yap1 triggers the recruitment of CD8+ T cells to attack the tumor. In contrast, females exhibit more immunosuppressive environments that prevent the same therapeutic benefit. Additionally, the research highlights the potential of targeting the CD276 (B7-H3) immune checkpoint to overcome these barriers. Ultimately, the findings suggest that biological sex is a vital factor in determining the effectiveness of immunotherapies for pediatric brain cancer.

References:

• Abdelfattah N, Natarajan S, Tran H N, et al. Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma[J]. Cancer Cell, 2026.